Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Statins and Venous Thromboembolic Disease - Where are we Now?
Curr Vasc Pharmacol. 2024 Mar 4. doi: 10.2174/0115701611308323240229050237. Online ahead of print.ABSTRACTClassical risk factors for atherosclerosis also play a role in the pathogenesis of venous thromboembolism (VTE). Low-density lipoprotein cholesterol has prothrombotic and endothelium- deteriorating effects which are not limited to the arterial system. The association between hypercholesterolemia and VTE has been established, but the benefits of statins in the prevention of VTE assessed by observation studies seemed equivocal. The large, randomized trial Justification for the Use of Statins in Prevention: an Interventio...
Source: Current Vascular Pharmacology - March 5, 2024 Category: Drugs & Pharmacology Authors: Pavel Poredo š Debabrata Mukherjee Ale š Blinc Source Type: research
Effect of Intermittent Fasting on Lipid Profile, Anthropometric and Hepatic Markers in Non-Alcoholic Fatty Liver Disease (NAFLD): A Systematic Review
CONCLUSION: Any form of IF could be potentially beneficial for NAFLD treatment and some associated cardiometabolic parameters. However, it is necessary to evaluate the effects and safety of IF in long-term studies involving a higher number of participants with different stages of NAFLD. The effect of IF on NAFLD-associated vascular risk also needs evaluation.PMID:38321893 | DOI:10.2174/0115701611285401240110074530 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 7, 2024 Category: Drugs & Pharmacology Authors: Mar ía Fernanda Castillo Daniela Salgado-Canales Marco Arrese Francisco Barrera Dimitri P Mikhailidis Source Type: research
Peripheral Arterial Disease: An Underestimated Aspect of Menopause-related Cardiovascular Disease
Curr Vasc Pharmacol. 2024 Jan 24. doi: 10.2174/0115701611295374231212110458. Online ahead of print.NO ABSTRACTPMID:38321894 | DOI:10.2174/0115701611295374231212110458 (Source: Current Vascular Pharmacology)
Source: Current Vascular Pharmacology - February 7, 2024 Category: Drugs & Pharmacology Authors: Panagiotis Anagnostis Dimitri P Mikhailidis Ales Blinc Mojca Jensterle Mateja K Je žovnik Gerit Holger Schernthaner Pier Luigi Antignani Katica Bajuk Studen Miso Sabovic Pavel Poredos Source Type: research
Efficacy and Safety of Bempedoic Acid in Patients with High Cardiovascular Risk: An Update
Curr Vasc Pharmacol. 2024 Feb 7. doi: 10.2174/0115701611290763240126045433. Online ahead of print.ABSTRACTStatins play a significant role in the prevention of cardiovascular (CV) diseases (CVDs); however, non-adherence with statin treatment or statin intolerance (mainly attributed to muscleassociated side effects) is not uncommon. New agents such as bempedoic acid (BA) can provide more treatment options. BA is administered orally, once daily, at a dose of 180 mg in current clinical practice. It can decrease circulating low-density lipoprotein cholesterol (LDL-C) levels by nearly 30% as monotherapy or by 20% as an add-on to...
Source: Current Vascular Pharmacology - February 7, 2024 Category: Drugs & Pharmacology Authors: Ozge Telci Caklili Manfredi Rizzo Mustafa Cesur Source Type: research
